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ABSTRACT 
Objective: A new precise, accurate, sensitive and robust RP-HPLC method was developed for estimation of darunavir ethanolate in bulk and tablets. 
Methods: The chromatographic separation was achieved on Enable C18
Results: The method was linear over the concentration range of 40-90 µg/ml (r
 column (250 × 4.6 mm, 5 µm) at an ambient temperature. The mobile phase 
consists of acetonitrile and 0.01M potassium acetate buffer, pH 5.1 (75:25 v/v) was at the flow rate 1 ml/min and UV detection was done at 268 nm. 
2
Conclusion: It can be concluded from the results that the proposed RP-HPLC method was found to be rapid, simple, accurate, robust and precise for 
the analysis of darunavir ethanolate in bulk and tablet dosage form. The developed method can be applied in routine analysis of this drug in the 
pharmaceutical industry. 
= 0.998) of the drug. The percentage content was found in 
darunavir ethanolate 99.19±0.58 in tablets. The low value of the drug %RSD (0.11) indicates that reproducibility of this method. Low value of LOD 
and LOQ suggests the sensitivity of the method.  
Keywords: Darunavir ethanolate, Validation and RP-HPLC. 
 
INTRODUCTION 
Darunavir ethanolate is an oral anti-retroviral agent which selectively 
inhibits the cleavage of Human immunodeficiency virus (HIV-1) 
encoded Gag-polyproteins in infected cell, thereby preventing the 
formation of mature virus. Darunavir ethanolate has robust 
interaction with the protease enzyme from many strains of HIV. It 
blocks HIV protease enzyme which is needed for HIV to multiply. 
Darunavir Ethanolate is chemically [(1S, 2R)-3-[[(4-aminophenyl) 
sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl) 
propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b] furan-3-yl 
ester monoethanolate [1] (fig. 1). Literature survey revealed that some 
methods had been developed for determination of darunavir 
ethanolate by HPLC [2-4], HPTLC [5] and Spectrophotometric method 
[6]. Reported HPLC methods require more time for analysis of one 
sample and less number of samples may be analyzed. Therefore, the 
present work involves the development of a rapid RP-HPLC method 
for estimation of darunavir ethanolate in bulk and tablet dosage form 
and may be suitable for an industry as more number of samples can be 
analyzed in the given time period. 
 
 
Fig. 1: Chemical structure of darunavir ethanolate 
 
MATERIALS AND METHODS 
Chemicals and reagents 
The reference standard of darunavir ethanolate was provided by 
Cipla Ltd, Aurangabad, India “Daruvir®
Instruments  
-300 mg” tablets were 
procured from local pharmacies. The acetonitrile (HPLC grade) and 
potassium acetate of (AR grade) was provided by hind media Lab 
Pvt. Ltd, Mumbai, India. 
Shimadzu LC2010 HPLC system, Elga Lab water (PURE LAB UHQ-II) 
water purification system for HPLC study. Shimadzu model AY-120 
balance, Enable C18
Preparation of standard stock solutions 
 column, LC solution software was used. 
Darunavir ethanolate (100 mg) was transferred to 100 ml of the 
volumetric flask, dissolved in acetonitrile and diluted up to the mark. 
The standard stock solution was further diluted to obtain six 
different concentrations between 40-90µg/ml. The 20 µl volume of 
each solution was injected into the HPLC system under the 
optimized chromatographic conditions.  
Assay of tablet formulation 
20 tablets of “Daruvir®
RESULTS AND DISCUSSION 
-300” were weighed correctly and crushed to 
fine powder using a glass mortar and pestle. A portion equivalent to 
about 100 mg of darunavir ethanolate was correctly weighed and 
transferred to 100 ml volumetric flask. The powder was dissolved in 
acetonitrile, sonicated for 10 min and diluted up to the mark. The 
solution was further diluted with acetonitrile and filtered using what 
man filter paper no. 41. The filtrate was diluted to obtain 70µg/ml of 
drug and injected (in triplicate) to HPLC system. 
Selection of detection wavelength 
Analytical wavelength was selected by taking the absorption 
spectrum of darunavir ethanolate which gave λmax of darunavir 
ethanolate. A Stock solution of the drug was prepared in acetonitrile 
and a UV spectrum of 100 µg/ml solution of darunavir ethanolate 
was scanned in the range 200-400 nm. UV spectrum (fig. 2) showed 
maximum absorbance at 268 nm. Hence, wavelength 268 nm was 
selected for the further studies. 
Optimization of chromatographic conditions 
The HPLC method was optimized with a view to develop an assay 
method for darunavir ethanolate. Initially, different columns, 
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different combinations of mobile phases such as methanol: water 
and Acetonitrile: Potassium Acetate in different proportions, were 
tried at different flow rates. Finally, A mobile phase consisting 
acetonitrile and 0.01M potassium acetate buffer, pH 5.1 (75:25 v/v) 
at the flow rate 1 ml/min was selected. The injection volume was 20 
µl. The analysis was performed at an ambient temperature with UV 
detection at 268 nm. The Chromatogram of darunavir ethanolate is 
shown in fig. 3 and the optimized chromatographical conditions are 
mentioned in table 1. The retention time of the drug is 3.85 min 
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Fig. 2: UV-Spectrum of darunavir ethanolate in acetonitrile 
(100µg/ml) 
 
Table 1: Optimized chromatographic conditions 
Parameters Details 




, 250 mm x 4.6 mm, 5 µm 
1.0 ml/minute 




Injection volume 20 µl 
Run time 10 min 
Retention time (min.) 3.85+0.02 
Diluent Acetonitrile: potassium acetate (75:25 v/v) 
(pH5.1) 
 
Assay of tablet formulation 
The value of % drug found to be 100.3±0.58 in assay study which is 
satisfactory. The results of assay study are shown in table 3. 
Method validation [7-9] 
Validation of an analytical procedure is the process by which it is 
established by laboratory studies that the performance 
characteristics of the procedure meet the requirements for the 
intended analytical application. The developed chromatographic 
method was validated for system suitability, linearity and range, 
accuracy, precision, and robustness as per ICH guidelines [10]. 
Linearity and range 
Linearity was evaluated on a set of six standard solutions containing 
40-90 μg/ml, for darunavir ethanolate. The relationship between 
peak area (as a dependent variable) and concentration of the drug in 
the solution (as an independent variable) was established by the 
simple linear regression method. Calibration curve was constructed 
by plotting an average peak area vs concentration as shown in fig. 4. 
The regression equation was obtained as a calibration curve. 
 
 
Fig. 3: Chromatogram of darunavir ethanolate 
 
 
Fig. 4: Calibration curve of darunavir ethanolate 
 
Table 3: Results of assay of darunavir ethanolate 
S. No. Sample solution concentration (µg/ml) Sample solution area Mean sample solution area %Drug found 
1 70 3188057 3182058 100.3±0.58 
2 70 3180406 
3 70 3177712 
 
The value of R2
Limit of detection (LOD) and limit of quantification (LOQ) 
 is found to be 0.9982, which indicates that the 
calibration curve is linear in the concentration range of 40-90 μg/ml. 
Five sets of known concentrations (40-90 μg/ml) were prepared. 
Calibration curves were plotted for each set. LOD and LOQ were 







Where, SD = Standard Deviation of response  
S = Average of the slope of the calibration curve 
The LOD and LOQ were calculated as 0.234 µg/ml and 0.734 µg/ml, 
respectively, which indicate the method is sensitive.  
Precision 
(i) Repeatability 
In repeatability, six standard solutions were prepared each having a 
concentration of 70µg/ml of darunavir ethanolate. The response of 
each of these solutions was measured and percentage relative 
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standard deviation (% RSD) was calculated. The results are 
mentioned in table 4. 
(ii) Intermediate precision 
For intraday precision, nine different solutions were prepared 
across the intended range (60, 70 and 80 µg/ml) with three 
replicates of each, and their area was measured on the same day. For 
interday precision, nine different solutions were prepared across the 
intended range (60, 70 and 80 µg/ml) with three replicates of each, 
and their corresponding area was measured on three subsequent 
days. The results were reported in terms of the relative standard 
deviation (RSD) table 5(a) & 5(b). 
 
Table 4: Results for method precision (repeatability) 
















Table 5 (a): Intraday precision studies 




60 2795891 2788966±6176.946 0.2214 
60 2786981 
60 2784025 
70 3188057 3182058±5366.788 0.1686 
70 3180406 
70 3177712 







Table 5 (b): Inter-day precision studies 




60 2795890 2788985±6152.44 0.2205 
60 2786981 
60 2784085 
70 3144329 3165858±18890.26 0.5966 
70 3179660 
70 3173584 








The value of % RSD in repeatability, intraday precision and intraday precision indicate that method is precise. 
 
Table 6: Results of recovery study for darunavir ethanolate 





3373533 72.72 101.01 100.33+0.583124 0.58 
3351109 72.24 100 





3579287 77.20 96.5 96.60+0.115902 
 
0.11 
3587541 77.38 96.73 





3973756 85.78 97.47 97.19+0.275015 
 
0.27 
3962042 85.53 97.19 
3951109 85.29 96.92 
 
Table 7: Robustness data for darunavir ethanolate 
Factor Level %RSD 
 A: Change in flow rate 
0.9 -1 0.3149 
1 0 0.3147 
1.1 +1 0.6244 
 B: Change in temperature 
24 ° C -1 0.2501 
25 ° C 0 0.2502 
26 ° C +1 0.2471 
 C: Change in wavelength 
267 nm -1 0.7322 
268 nm 0 0.7279 
269 nm +1 0.7229 
Jain et al. 




Robustness of the above method was carried out by purposefully 
varying some chromatographic method parameters. These 
parameters include changes in the flow rate (0.9 ml and 1.1 ml), 
temperature (24 °C and 26 °
Recovery studies were performed at 80.0%, 100.0% and 120.0% 
levels using the standard addition method. Standard drug solution of 
darunavir ethanolate was spiked at 80.0%, 100.0% and 120.0%. For 
each level, three replicate were prepared and injected in the column 
under optimized HPLC conditions.  
The calculation for accuracy of darunavir ethanolate was performed 
and the results are expressed in terms of % recovery±SD and % R. S. 
D values (table 6). The values of % recovery at each level are found 
within acceptance criteria that indicate the method is accurate. 
CONCLUSION  
C) and wavelength (267 nm and 269 
nm). The results obtained by changing these conditions are obtained 
in terms of % RSD values. The values % RSDs are given in table 7. 
These values are within acceptance an criterion which indicates that 
the developed method is robust. 
Accuracy  
The present work represents the report that deals with analysis of 
darunavir ethanolate in bulk and tablet dosage forms using RP-
HPLC. It can be concluded from the results that the proposed 
method is simple, accurate, robust and precise.  
This method was validated as per ICH guidelines. Thus, it can be used 
for routine quality control studies for assay of darunavir ethanolate. 
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